Nothing Special   »   [go: up one dir, main page]

JO3330B1 - الأجسام المضادة cgrp - Google Patents

الأجسام المضادة cgrp

Info

Publication number
JO3330B1
JO3330B1 JOP/2011/0177A JOP20110177A JO3330B1 JO 3330 B1 JO3330 B1 JO 3330B1 JO P20110177 A JOP20110177 A JO P20110177A JO 3330 B1 JO3330 B1 JO 3330B1
Authority
JO
Jordan
Prior art keywords
cgrp
antibodies
cgrp antibodies
antigen
binding fragment
Prior art date
Application number
JOP/2011/0177A
Other languages
English (en)
Inventor
Allan Barrett
Jan Benschop Robert
James Darling Ryan
Geoffrey Chambers Mark
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3330B1 publication Critical patent/JO3330B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

يقدم الاختراع الحالي أجسام مضادة بشرية معدلة وراثيًا للببتيد المرتبط بجين كالسيتونين (CGRP) أو شظية الارتباط بمولد الضد منها. بالإضافة إلى ذلك، يقدم الاختراع الحالي استخدام الأجسام المضادة البشرية المعدلة وراثيًا للببتيد المرتبط بجين كالسيتونين (CGRP) أو شظية الارتباط بمولد الضد منها وذلك لعلاج ألم الالتهاب العظمي المفصلي.
JOP/2011/0177A 2010-06-10 2011-05-31 الأجسام المضادة cgrp JO3330B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35332310P 2010-06-10 2010-06-10

Publications (1)

Publication Number Publication Date
JO3330B1 true JO3330B1 (ar) 2019-03-13

Family

ID=45096388

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0177A JO3330B1 (ar) 2010-06-10 2011-05-31 الأجسام المضادة cgrp

Country Status (34)

Country Link
US (3) US9073991B2 (ar)
EP (2) EP2579894B1 (ar)
JP (2) JP6021806B2 (ar)
KR (1) KR101489566B1 (ar)
CN (2) CN104292332B (ar)
AR (1) AR081434A1 (ar)
AU (1) AU2011265050B2 (ar)
BR (1) BR112012031501B1 (ar)
CA (1) CA2802102C (ar)
CY (2) CY1119789T1 (ar)
DK (1) DK2579894T3 (ar)
EA (1) EA022931B1 (ar)
ES (2) ES2930321T3 (ar)
HK (1) HK1203211A1 (ar)
HR (1) HRP20171992T1 (ar)
HU (2) HUE038135T2 (ar)
IL (2) IL222885B (ar)
JO (1) JO3330B1 (ar)
LT (2) LT2579894T (ar)
LU (1) LUC00112I2 (ar)
ME (1) ME02862B (ar)
MX (2) MX363209B (ar)
NL (1) NL300979I2 (ar)
NO (2) NO2579894T3 (ar)
NZ (1) NZ603607A (ar)
PL (1) PL2579894T3 (ar)
PT (1) PT2579894T (ar)
RS (1) RS56638B1 (ar)
SG (1) SG185648A1 (ar)
SI (1) SI2579894T1 (ar)
TW (1) TWI423818B (ar)
UA (1) UA109658C2 (ar)
WO (1) WO2011156324A1 (ar)
ZA (1) ZA201208996B (ar)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3842458A1 (en) 2005-11-14 2021-06-30 Teva Pharmaceuticals International GmbH Antagonist antibodies directed against calcitonin gene-related peptide
EP3441087A1 (en) 2008-03-04 2019-02-13 Teva Pharmaceuticals International GmbH Methods of treating chronic pain
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
US9708393B2 (en) 2011-05-20 2017-07-18 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
WO2012162243A2 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
JP6568099B2 (ja) 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6581656B2 (ja) 2014-10-24 2019-09-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． グルカゴンおよびｇｌｐ−１受容体のコアゴニスト
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
JP6592600B2 (ja) * 2015-10-30 2019-10-16 イーライ リリー アンド カンパニー 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用
CN105483091A (zh) * 2015-12-29 2016-04-13 天津三箭生物技术股份有限公司 小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
JP2019501152A (ja) * 2016-01-28 2019-01-17 イーライ リリー アンド カンパニー Ｃｇｒｐ抗体及びその使用
EP3411066A1 (en) 2016-02-01 2018-12-12 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds
CN109996544A (zh) 2016-06-27 2019-07-09 加利福尼亚大学董事会 癌症治疗组合
EP3515937A1 (en) * 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Treating refractory migraine
US20180111984A1 (en) 2016-09-23 2018-04-26 Teva Pharmaceuticals International Gmbh Treating cluster headache
MX2019010397A (es) 2017-03-02 2020-08-20 Beth Israel Deaconess Medical Ct Inc Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
TW201902926A (zh) * 2017-05-03 2019-01-16 美商美國禮來大藥廠 抗cgrp／抗il-23雙特異性抗體及其用途
EP3642218A4 (en) * 2017-06-21 2021-04-07 Cephalon, Inc. CATION EXCHANGE CHROMATOGRAPHY WASH PAD
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
UY38050A (es) 2018-01-12 2019-07-31 Amgen Inc Anticuerpos pac1 y sus usos referencia cruzada a solicitudes relacionadas
WO2019231800A1 (en) 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
WO2020041468A1 (en) 2018-08-22 2020-02-27 Eli Lilly And Company Anti-cgrp antibodies for treatment-resistant patients
CN113227140A (zh) 2019-01-08 2021-08-06 H.隆德贝克有限公司 使用抗cgrp抗体急性治疗和快速治疗头痛
EP3744400A1 (en) * 2019-05-28 2020-12-02 Etablissement Français du Sang Car-t cells targeting il-1rap and their use in acute myeloid leukemia (aml)
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
JP7551744B2 (ja) 2019-10-15 2024-09-17 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
CA3212151A1 (en) 2021-03-02 2022-09-09 Cgrp Diagnostics Gmbh Treatment and/or reduction of occurrence of migraine
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
CN117586390A (zh) * 2022-08-11 2024-02-23 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途
CN118271438B (zh) * 2024-05-27 2024-08-30 上海宏成药业有限公司 抗cgrp抗体或其抗原结合片段及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
RU2139351C1 (ru) * 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US20060228367A1 (en) * 2005-04-08 2006-10-12 Medimmune, Inc. Antibodies against mammalian metapneumovirus
EP3842458A1 (en) * 2005-11-14 2021-06-30 Teva Pharmaceuticals International GmbH Antagonist antibodies directed against calcitonin gene-related peptide
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
EP3441087A1 (en) * 2008-03-04 2019-02-13 Teva Pharmaceuticals International GmbH Methods of treating chronic pain
EP3115062A1 (en) 2008-03-04 2017-01-11 Labrys Biologics Inc. Methods of treating inflammatory pain
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp

Also Published As

Publication number Publication date
NL300979I1 (nl) 2019-04-17
US20150259415A1 (en) 2015-09-17
EP3318272A1 (en) 2018-05-09
US9505838B2 (en) 2016-11-29
CN104292332A (zh) 2015-01-21
JP2017014203A (ja) 2017-01-19
HK1203211A1 (en) 2015-10-23
MX340999B (es) 2016-08-03
EP2579894B1 (en) 2017-11-22
LT2579894T (lt) 2018-02-26
TWI423818B (zh) 2014-01-21
PL2579894T3 (pl) 2018-04-30
CA2802102A1 (en) 2011-12-15
JP6466883B2 (ja) 2019-02-06
IL222885B (en) 2019-09-26
NO2019017I1 (no) 2019-04-05
LUC00112I2 (ar) 2019-12-27
NZ603607A (en) 2014-09-26
US9073991B2 (en) 2015-07-07
HUE038135T2 (hu) 2018-09-28
KR20130034024A (ko) 2013-04-04
US20110305711A1 (en) 2011-12-15
IL222885A0 (en) 2012-12-31
IL242409B (en) 2020-07-30
CY2019017I1 (el) 2020-05-29
ES2930321T3 (es) 2022-12-09
TW201210618A (en) 2012-03-16
RS56638B1 (sr) 2018-03-30
WO2011156324A1 (en) 2011-12-15
CA2802102C (en) 2016-07-26
US20170073403A1 (en) 2017-03-16
DK2579894T3 (en) 2018-01-15
UA109658C2 (xx) 2015-09-25
CY2019017I2 (el) 2020-05-29
LUC00112I1 (ar) 2019-04-10
BR112012031501B1 (pt) 2020-02-11
CN102946905B (zh) 2014-10-15
ES2656000T3 (es) 2018-02-22
EP2579894A1 (en) 2013-04-17
EP3318272B1 (en) 2022-08-10
MX363209B (es) 2019-03-14
AU2011265050B2 (en) 2013-06-27
SG185648A1 (en) 2012-12-28
HRP20171992T1 (hr) 2018-02-09
AU2011265050A1 (en) 2012-11-08
CN102946905A (zh) 2013-02-27
KR101489566B1 (ko) 2015-02-03
EA201270769A1 (ru) 2013-04-30
JP6021806B2 (ja) 2016-11-09
SI2579894T1 (en) 2018-01-31
MX2012014480A (es) 2013-02-07
ME02862B (me) 2018-04-20
JP2013532143A (ja) 2013-08-15
CN104292332B (zh) 2019-11-01
NL300979I2 (nl) 2019-07-11
EP2579894A4 (en) 2013-12-04
LTPA2019011I1 (lt) 2019-05-10
LTC2579894I2 (lt) 2020-03-25
EA022931B1 (ru) 2016-03-31
AR081434A1 (es) 2012-08-29
PT2579894T (pt) 2018-02-06
BR112012031501A2 (pt) 2016-10-25
NO2579894T3 (ar) 2018-04-21
HUS1900020I1 (hu) 2019-05-28
ZA201208996B (en) 2014-05-28
CY1119789T1 (el) 2018-06-27

Similar Documents

Publication Publication Date Title
JO3330B1 (ar) الأجسام المضادة cgrp
MX355268B (es) Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos.
MX355543B (es) Macrociclos peptidomiméticos.
EA201290557A1 (ru) Пептидный аналог оксинтомодулина
NZ587292A (en) Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain
MX2017016502A (es) Anticuerpos contra cd40 con actividad agonista mejorada.
SG194701A1 (en) Anti-cd40 antibodies and methods of use
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2009012343A (es) Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
MX341578B (es) Tratamiento de la osteoartritis y del dolor.
MX350234B (es) Compuestos de enlace especificos de bacterias gram-positivas.
EA201490039A1 (ru) Химерные и гибридные полипептиды фактора viii и способы их применения
MX2014015830A (es) Anticuerpos lsr y usos de los mismos para el tratamiento de cancer.
MY172292A (en) Vectors and sequences for the treatment of diseases
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
MX2011010707A (es) Anticuerpos dkk-1.
NZ626242A (en) Anti-asic1 antibodies and uses thereof
NZ607588A (en) Antibodies against human TWEAK and uses thereof
TN2015000277A1 (en) Bmp-6 antibodies
MX341020B (es) Peptidos derivados de lactoferrina humana y su uso.
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
MX2013011629A (es) Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.